Discontinuation report SANDOZ FINASTERIDE
| Report ID | 141663 |
| Drug Identification Number | 02322579 |
| Brand name | SANDOZ FINASTERIDE |
| Common or Proper name | SANDOZ FINASTERIDE |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | FINASTERIDE |
| Strength(s) | 5MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 500FCT BO CA |
| ATC code | G04CB |
| ATC description | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2021-06-29 |
| Remaining supply date | 2021-06-29 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2021-06-30 | French | Compare |
| v1 | 2021-06-30 | English | Compare |
Showing 1 to 2 of 2